PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
暂无分享,去创建一个
D. Grandér | K. Young | L. Kis | G. Rassidakis | L. Medeiros | E. Drakos | T. Panaretakis | T. Panaretakis | V. Leventaki | G. Rassidakis | K. Young | N. Tsesmetzis | V. Atsaves | D. Chioureas | Nikolaos Tsesmetzis | Dimitris Chioureas | Vasiliki Leventaki
[1] A. Kwiecińska,et al. CD274 (PD‐L1)/PDCD1 (PD‐1) expression in de novo and transformed diffuse large B‐cell lymphoma , 2018, British journal of haematology.
[2] Y. Natkunam,et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Tzankov,et al. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. , 2016, Human pathology.
[4] Kui Wu,et al. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. , 2016, Blood.
[5] D. Felsher,et al. MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.
[6] C. Jiang,et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] A. Rosenwald,et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. , 2015, Cancer cell.
[8] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[9] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[10] M. Shipp,et al. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies , 2013, Clinical Cancer Research.
[11] M. Wasik,et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) , 2008, Proceedings of the National Academy of Sciences.
[12] G. Rassidakis,et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] D N Shapiro,et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.
[14] A. Rosenwald,et al. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. , 2015, Blood.
[15] E. Campo,et al. The World Health Organization Classification of Lymphoid Neoplasms , 2013 .
[16] Roberto Piva,et al. The anaplastic lymphoma kinase in the pathogenesis of cancer , 2008, Nature Reviews Cancer.